2024 World Conference on Lung Cancer (WCLC) - Posters-P2.11C.03 Immune-Related Adverse Events are Associated with Survival in Chinese Lung Cancer Patients Treated With Immunotherapy

P2.11C.03 Immune-Related Adverse Events are Associated with Survival in Chinese Lung Cancer Patients Treated With Immunotherapy

Pdf Summary

This study explores the link between immune-related adverse events (irAEs) and overall survival (OS) in Chinese lung cancer patients treated with immune checkpoint inhibitors (ICIs). In particular, it focuses on two common irAEs: immune-related hepatitis (IRH) and immune-related pneumonitis (IRP). Conducted as a retrospective analysis using data from the Lung Cancer Tracking Cohort (LCTC) at Hunan Cancer Hospital, the study includes clinical information from 3,261 lung cancer patients treated with ICIs from January 2018 to December 2023.<br /><br />The study employed multivariate Cox-proportional hazard models with time-varying covariates, addressing potential immortal time bias. Landmark analyses were conducted at specific intervals (3, 6, 9, and 12 months) to further validate findings. Covariates such as age, gender, cancer stage, smoking status, and other factors were adjusted for.<br /><br />The findings indicate that patients with IRH had significantly longer OS, particularly in cases of mild IRH, which could serve as a potential indicator of favorable treatment outcomes. However, no similar beneficial effect on OS was found for patients with IRP. Severe cases of IRH and IRP lacked statistical significance due to insufficient data, indicating the need for further research involving larger datasets to confirm these observations.<br /><br />Acknowledging F. Hoffmann-La Roche Ltd.'s support in sample sequencing, the study underlines the critical importance of proactive and timely irAE management to enhance the benefit-risk balance for patients on ICIs. Despite the risks associated with irAEs, their potential association with better OS presents an intriguing avenue for improving patient outcomes in lung cancer treatment.

Asset Subtitle

Yongchang Zhang

Meta Tag

Speaker Yongchang Zhang

Topic Metastatic NSCLC – Immunotherapy

Keywords

immune-related adverse events

overall survival

lung cancer

immune checkpoint inhibitors

immune-related hepatitis

immune-related pneumonitis

Cox-proportional hazard models

landmark analysis

treatment outcomes

Hunan Cancer Hospital